NEW YORK (GenomeWeb News) – MetaStat today said it has reached two exclusive licensing agreements for the use of alternatively spliced mRNA and protein isoform biomarkers.

The agreements are with the Massachusetts Institute of Technology and its David H. Koch Institute for Integrative Cancer Research at MIT and its department of biology, the Albert Einstein College of Medicine of Yeshiva University, and Montefiore Medical Center. The technology being licensed is for the diagnosis, prognosis, and treatment of metastasis in epithelial solid tumor cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.